Call scheduled for today, May 13, at 4:30 pm ET TUCSON, Ariz. , May 13, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31,
TUCSON, Ariz. , May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the quarter ended March 31, 2021 after the market close on Thursday,
TUCSON, Ariz. , April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain preliminary financial results for the first quarter ended March 31, 2021 .
Call scheduled for today, March 25, at 4:30pm ET TUCSON, Ariz. , March 25, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the year ended December 31, 2020
TUCSON, Ariz. , March 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on
TUCSON, Ariz. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq
Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director TUCSON, Ariz. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that Timothy
Preliminary full year 2020 unaudited revenue of $8.5 million Cash, cash equivalents and short-term marketable securities of $28.7 million as of December 31, 2020 TUCSON, Ariz. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose
TUCSON, Ariz. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease
TUCSON, Ariz. , Dec. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its
